( LSE:GSK,NYSE:GSK,NYSE:PFE )

News from ViiV Healthcare A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 18, 2016, 06:15 ET ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior...


Feb 24, 2016, 12:12 ET ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented...


Feb 23, 2016, 14:49 ET ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen...


Jan 19, 2016, 08:30 ET ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

 ViiV Healthcare and the Los Angeles Department of Health Services (LA DHS) today announced the launch of the ViiV Healthcare/LA DHS HIV Public...


Jan 07, 2016, 08:31 ET ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration...


Nov 03, 2015, 08:24 ET ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb...


May 26, 2015, 09:00 ET ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an...


May 06, 2015, 04:51 ET ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine   ViiV Healthcare today announced the start of a...


Feb 04, 2015, 09:30 ET ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

 ViiV Healthcare today announced the launch of a four-year, $10 million initial investment to fuel a concerted community response to the HIV...